01-03-2020 | NSCLC | Letter to the Editors
PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab
Published in: Cancer Immunology, Immunotherapy | Issue 3/2020
Login to get access01-03-2020 | NSCLC | Letter to the Editors
Published in: Cancer Immunology, Immunotherapy | Issue 3/2020
Login to get access